Guangxi Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Nanning China (1934)

Organization Overview

First Clinical Trial
2006
NCT00615667
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

1st Affiliated Hospital, Guangxi Medical University | Affiated Tumor Hospital of Guangxi Medical University | Affiliated hospital of guangxi medical university,china | Affiliated Tumor Hospital, Guangxi Medical University | Affiliated Tumor of Guangxi University | Cancer Hospital Affiliated to Guangxi Medical University | Cancer Hospital of Guangxi Medical University | Cancer Institute of Guangxi Zhuang Autonomous Region | Chengcheng Liao, Affiliated Tumor Hospital, Guangxi Medical | Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University | Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University,Guangxi | Department of Radiation Oncology, People's Hospital of Guangxi Zhuang Autonomous Region | Fourth Affiliated Hospital of Guangxi Medical University | Guangxi Cancer Hospital | Guangxi Longtan hospital | Guangxi Medical University | Guangxi Medical University Affiliated Cancer Hospital | Guangxi Medical University Cancer Center | Guangxi Medical University Cancer Hospital | Guangxi Medical University First Affiliated Hospital | Guangxi Medical University Institutional Review Board | Guangxi Nanxishan Hospital | Guangxi Naxishan Hospital | Guangxi Ruikang Hospital | Guangxi Traditional Chinese Medical University | Guangxi University of Chinese Medicine | GXMU | Institute of Respiratory Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning 530021, Guangxi, China | Liuzhou Cancer Hospital | Liuzhou City hospital | Liuzhou City hospital of TCM | Liuzhou Hospital of Traditional Chinese Medicine | Liuzhou Maternity and Child Healthcare Hospital | Liuzhou People's Hospital | Liuzhou traditional Chinese medicine hospital | Liuzhou Worker's Hospital | Maternal and Child Health Hospital of Guangxi Province | Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region | Maternal and Child Health Hospital of Nanning City | Maternal & Child Health Hospital of Guangxi Zhuang Autonomous Region | Nanning maternal and Child Health Hospital | Nanning Monority Hospital | Nanning Second People's Hospital | National Hospital of Guangxi Zhuang Autonomous Region | People's Hospital of Guangxi | Second Affiliated Hospital of Guangxi Medical University | The First Affiliated Hospital of Guangxi Medical University, China | The First Affiliated Hospital of Guangxi University of Chinese Medicine | The First Affiliate Hospital of Guangxi Medical College | The first affliated hospital of Guangxi medical university | The People's hospital of Guangxi Zhuang Autonomous | The People's hospital of LiuZhou | The third Affiliated Hospital of Guangxi Medical University | Yang Zhijun | Yong Zhang,MD

Active Ingredients

Drugs in Phase 4 Trials (33)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (2 trials)

basiliximab (simulect) (3 trials)

busulfan (myleran) (2 trials)

cyclophosphamide (cytoxan) (5 trials)

cyclosporine (sandimmune) (3 trials)

deng zhan sheng mai (1 trial)

entecavir (baraclude) (4 trials)

fludarabine (fludara) (2 trials)

flurbiprofen (ansaid) (1 trial)

fuganlin (1 trial)

fuzhenghuayu (2 trials)

lamivudine (epivir) (3 trials)

levetiracetam (keppra) (1 trial)

lopinavir (Kaletra) (3 trials)

methotrexate (2 trials)

mycophenolate (myfortic) (5 trials)

naltrexone (revia) (2 trials)

nevirapine (viramune) (1 trial)

parecoxib (1 trial)

phenobarbital (1 trial)

propofol (diprivan) (2 trials)

qiliqiangxin (1 trial)

ritonavir (Norvir) (2 trials)

ruxolitinib (jakafi) (1 trial)

sevoflurane (ultane) (2 trials)

sodium chloride (2 trials)

somatropin (protropin) (1 trial)

tacrolimus (prograf) (4 trials)

tenecteplase (tnkase) (1 trial)

tirofiban (aggrastat) (1 trial)

xiaoer jiebiao (1 trial)

xingnaojing (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 3 Trials (44)

2B4.11 (1 trial)

albumin (Human) (Plasbumin) (1 trial)

allopurinol (zyloprim) (1 trial)

apatinib (8 trials)

autologous cytokine induced killer cells (2 trials)

azathioprine (imuran) (1 trial)

camrelizumab (5 trials)

capecitabine (xeloda) (5 trials)

carboplatin (paraplatin) (2 trials)

celecoxib (celebrex) (2 trials)

cetuximab (erbitux) (2 trials)

cisplatin (platinol) (16 trials)

ctl (1 trial)

docetaxel (taxotere) (7 trials)

doxorubicin (Doxil) (2 trials)

eadm (1 trial)

endostatin (endostar) (6 trials)

febuxostat (uloric) (1 trial)

fluorouracil (efudex) (12 trials)

gelatin (1 trial)

gemcitabine (gemzar) (7 trials)

irbesartan (avapro) (1 trial)

irinotecan (Camptosar) (2 trials)

lenvatinib (lenvima) (3 trials)

leucovorin (4 trials)

lipiodol (1 trial)

methylprednisolone (medrol) (2 trials)

nedaplatin (3 trials)

nivolumab (opdivo) (1 trial)

oxaliplatin (eloxatin) (5 trials)

paclitaxel (taxol) (3 trials)

prednisone (meticorten) (3 trials)

rc48-adc (1 trial)

rituximab (rituxan) (1 trial)

ropivacaine (naropin) (1 trial)

sitagliptin (januvia) (1 trial)

smoked plum (1 trial)

sorafenib (nexavar) (5 trials)

sufentanil (1 trial)

tenofovir (viread) (1 trial)

therarubicin (1 trial)

toripalimab (3 trials)

vincristine (oncovin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (24)

anlotinib (1 trial)

autologous umbilical cord blood (1 trial)

bicalutamide (casodex) (1 trial)

cik cells (3 trials)

dendritic cells (3 trials)

epirubicin (ellence) (1 trial)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (2 trials)

fruquintinib (1 trial)

gimeracil (1 trial)

gypenosides (1 trial)

icotinib (2 trials)

ifosfamide (ifex) (1 trial)

imatinib (gleevec) (1 trial)

nimotuzumab (1 trial)

oteracil (1 trial)

pegaspargase (oncaspar) (1 trial)

pemetrexed (alimta) (1 trial)

regorafenib (stivarga) (1 trial)

sintilimab (1 trial)

tegafur (1 trial)

temozolomide (temodar) (1 trial)

tislelizumab (2 trials)

urea (1 trial)

Drugs in Phase 1 Trials (1)

famotidine (pepcid) (1 trial)

Drugs in Other Trials (23)

artemisiacapillaris thunb (1 trial)

benazepril (lotensin) (1 trial)

donor regulatory t lymphocytes (1 trial)

febrifuge (1 trial)

fludeoxyglucose f-18 (1 trial)

gardenia jasminoides ellis (1 trial)

ginseng (1 trial)

immune globulin (human) (1 trial)

jianpixiaozhong (1 trial)

mannitol (1 trial)

norepinephrine (levophed) (1 trial)

paeoniae radix (1 trial)

remifentanil (ultiva) (1 trial)

rhizoma atractylodis macrocephalae (1 trial)

rhizoma pinelliae (1 trial)

rubia cordifolia (1 trial)

salvia miltiorrhiza extract (1 trial)

sieyesbeckiaorientalis (1 trial)

terlipressin (1 trial)

valsartan (diovan) (1 trial)

voriconazole (vfend) (1 trial)

wuling san (1 trial)

xiyanping (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

beta-Thalassemia (Phase 4)

Brain Diseases (Phase 2)

Brain Ischemia (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Cardiomyopathies (Phase 4)

Cardiomyopathy, Dilated (Phase 4)

Cerebral Infarction (Phase 4)

Cognitive Dysfunction (Phase 4)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 4)

Delirium (Phase 4)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Fallopian Tube Neoplasms (Phase 3)

Fibrosis (Phase 4)

Gastroesophageal Reflux (Phase 1)

Glioblastoma (Phase 2)

Glomerulonephritis, IGA (Phase 3)

Gout (Phase 3)

Graft vs Host Disease (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

HIV Infections (Phase 4)

Hypoproteinemia (Phase 3)

Hypothermia (Phase 2)

Hypoxia-Ischemia, Brain (Phase 2)

Infarction (Phase 2)

Infections (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Liver Cirrhosis (Phase 4)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, T-Cell (Phase 2)

Nasopharyngeal Carcinoma (Phase 3)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasm, Residual (Phase 2)

Nephritis (Phase 3)

Nephrosis (Phase 3)

Nephrotic Syndrome (Phase 3)

Neuritis (Phase 2)

Optic Neuritis (Phase 2)

Ovarian Neoplasms (Phase 3)

Pelvic Floor Disorders (Phase 3)

Peritoneal Neoplasms (Phase 3)

Philadelphia Chromosome (Phase 2)

Postoperative Complications (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Premature Birth (Phase 2)

Rectal Neoplasms (Phase 2)

Respiratory Tract Infections (Phase 4)

Seizures (Phase 4)

Small Cell Lung Carcinoma (Phase 2)

Stroke (Phase 4)

Syndrome (Phase 3)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 109
  • # of Trial APIs: 125